Excited to share the research that lead to @sniprbiome development candidate for selective targeting of E. coli in the gut using #CRISPR armed #phages

Microbes are already used for food production, yet, their potential for making new healthy and sustainable foods is far from exhausted. Learn more about the Microbial Foods field here: https://t.co/7pO8MDS6jF @CellCellPress @DTUBiosustain @novonordiskfond

Characterization of new #biosensors for E coli #Nissle to aid the design of Advanced #microbiome Therapeutics

Happy to share our collaborative work on the in vitro evaluation of Niclosamide in primary bronchial cells. #PLOSONE: Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a c ...

I’m really honored to be one of the recipients of this year’s Vilcek Prizes for Creative Promise. America is truly a land of opportunities. My parents immigrated to the US w/ nothing but dreams & hopes when I was young. I’m glad to be able to build a life and career here in 🇺🇸

An update on Delta, vaccination protection and viral loads from the aggregate data available, with new @PHE_uk data 1. Delta infections are characterized by very high viral loads (low Cts). When a breakthrough occurs, the load is similar to unvaccinated, but clears more rapidly

#Niclosamide has activity against Variants of Concern of #SARS_CoV_2, including B.1.1.7 and B.1.351. https://t.co/o2Sw8nl97G @UNION_Tx @DTUBiosustain @DTUtweet

Our new paper describes a computational framework for assessing future dissemination of antibiotic resistance genes based on the gene exchange networks of their mobile elements. @DTUBiosustain @DTUtweet @novonordiskfond @lundbeckfonden @NatureComms https://t.co/76zXL3VM7O

Data from this study support testing of UNI91104, a promising candidate for viral respiratory infections such as COVID19, in patient trials. Transient irritation in the upper respiratory tract was the most frequent adverse event. Nasal application did not result in any AE.

Excited to share Phase 1 results from @UNION_Tx inhaled & intranasal niclosamide formulation. The good HV tolerability and broad antiviral effect opens exciting perspectives for the treatment of respiratory infections - including #COVID19 https://t.co/wdlncOUY60 @DTUtweet

Yesterday we announced positive data from the first part of our phase 1 trial of SYNB8802. We are developing SYNB8802 as a potential treatment for patients who have high oxalate absorption from the GI tract which causes progressive kidney damage. How did we get here? 🧵 1/9

Happy to announce that our work on broadly protective nanoparticle-based influenza vaccines has been published in Nature! https://t.co/iwWQonNElz Supraseasonal flu vaccine = protects against seasonal flu even when that year's strain prediction is off, plus some more 1/9

The emergence of the #SARSCoV2 variants B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351) and P.1 (B.1.1.28.1) has aroused many concerns, including worsening #COVID19 and escape from vaccine-induced immunity.

Alternative proteins will transform food, mitigate climate change and drive profits. Here's how. @BCG https://t.co/CrtCFbifOg

Just out @TheLancet: Largest study of reinfection, whole country of Denmark —0.65% after prior covid —Protection ~80%, lasts ≥ 7 months —Age ≥ 65 protection reduced to 47% https://t.co/xMn3tKaja0 @SteenEtTo @uni_copenhagen @SSI_dk

🎧Podcast: Intelligente tarmbakterier behandler hjernesygdomme 🦠Mikrobiolog @moasommer fortæller om arbejdet med at udvikle skræddersyede mikrober som ‘levende medicin’ 👉 https://t.co/2uqNfUjZEe #dkforsk #sundpol

Using synthetic microbial communities mimicking the Brazilian sugarcane ethanol fermentation we reveal L. amylovorus as an industrial probiotic that may improve process yield. Our collaboration with @asanchez_lab is published in @NatureComms https://t.co/4XTcQ6byBo. @DTUtweet

Great blog post on the need for inhaled #antivirals for treatment of #COVID-19 in the community setting. https://t.co/MQo7qejdeI

Reduced viral loads 12 days following Pfizer-BioNTech #COVID19 vaccine. medRxiv (to appear soon). with @idanyelin @MatanLevine in collaboration with #MaccabiTech; @TechnionLive

"We found that combination therapy significantly limits the #evolution of de novo resistance in E. coli, yet different #drugcombinations vary substantially in their propensity to select for #AntibioticResistance" by @LeonieJJahn and @moasommer https://t.co/SakZOSAn6H